1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
2. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists’ Collaborative Group. Lancet 1995;346:265–269.
4. Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P,
et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014;15:e404–e414.
5. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS,
et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11–22.
6. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM,
et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215–1228.
7. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X,
et al. An integrated network of androgen receptor, polycomb, and
TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010;17:443–454.
9. Park ES, Kim SJ, Kim SW, Yoon SL, Leem SH, Kim SB,
et al. Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci U S A 2011;108:17456–17461.
11. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A,
et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297–1303.